Clinical Trial Update: An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ABT-925 for acute exacerbation of schizophrenia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABT-925

Snippet

Sponsor: Abbott | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED